Intervet sees 6% global growth

Outpacing market growth, EBIT before incidentals increased 2% to EUR 213 million, resulting in an EBIT margin of 18.9%. Divestments and acquisitions had a negative impact on revenues of 3%.

In Europe, autonomous growth was 5%, while in North America, revenues from ongoing operations grew 12%. At the end of the year, Intervet received important product approvals for Zilmax®, a feed additive for cattle and PreveNile®, a West Nile Virus vaccine for horses.

TheCattleSite News Desk

Sign up for our
regular news updates

Latest Cattle Industry News

•   FMD NEWS: Financial Impact of FMD in Focus
•   BLUETONGUE: Import Ban Call as Tally Hits 40
•   English Beef Efficiency on the Up Say EBLEX
•   CAP Health Check to Ease Plight of Farmers
•   Resilient Japanese Beef Market is Australia's Rock
•   COOL and Canada: What will US Consumers Choose?
•   AFBF: GHG Regulations to Result in a 'Livestock Tax'
•   Fonterra Revises Payout and Warns of Hard Times
•   Wairarapa Field Day to Unlock Dairy Potential
•   Irish Beef Reform Scuppered by Competition Ruling
•   USMEF Fosus on Beef Export Momentum
•   CME: How Long Before US Sees Price Decline?
•   Russia Sets Out Meat Quota for Imports
•   The Milky Way to Recovering the Chinese Dairy Sector
•   TB Reservoirs: Badger or Cattle Populations?